Markets
AbbVie EU Vitiligo Approval: What the Positive CHMP Opinion Means for ABBV Stock
AbbVie has secured a positive opinion from the European Medicines Agency's CHMP for its vitiligo treatment, moving the drug a step closer to full EU market authorisation. The regulatory milestone expands AbbVie's dermatology franchise and has clear implications for ABBV's revenue trajectory and stock valuation.